Not yet recruiting
Acute myeloid leukaemia+1
Not yet recruitingSafety and feasibility study of CARCIK‑CD123/33 cell therapy in adult and pediatric patients with relapsed or refractory AML and BPDCN
InvestigationalNo placebo
Safety and feasibility study of CARCIK‑CD123/33 cell therapy in adult and pediatric patients with relapsed or refractory AML and BPDCN
InvestigationalNo placebo
- Disease:Acute myeloid leukaemiaBlastic plasmacytoid dendritic cell neoplasia
- Substances:CARCIK-CD123/33
Countries:
Italy
Italy- Participants:0–17 years · 18–64 years · 65+ years
- Substances:CARCIK-CD123/33